Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epsolay in Papulopustular Rosacea
NCT03564119Phase 3Completed
- Sponsor
- Sol-Gel Technologies
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benzoyl peroxide + sulfur in papulopustular rosacea (2 arms), sponsored by Sol-Gel Technologies. Primary endpoints: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at 12 weeks and Change From Baseline in Inflammatory Lesion Counts at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
benzoyl peroxide + sulfur
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03564119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564119.